Jiang Z, et al. - This retrospective, single-center study included 203 ST-elevation myocardial infarction (STEMI) patients who had primary percutaneous coronary intervention (PCI), researchers examined the link between severity of inflammation and the impact of antiplatelet therapy (clopidogrel vs ticagrelor) following PCI. Findings demonstrated more potent platelet inhibition by ticagrelor vs clopidogrel at different inflammation levels. This indicated that ticagrelor might exert a more stable antiplatelet effect at higher levels of systemic inflammation. Furthermore, post-PCI follow-up revealed the association of ticagrelor with reduced indices of inflammation. This finding was suggestive of a possible role of anti-inflammatory effects in the clinical benefit observed with antiplatelet therapy.